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Resumen
Objetivos: exponer lo que se conoce acer-
ca de tres niveles de toma de decisión sobre 
tratamiento en el encuentro medico: (1) inter-
cambio de información, (2) deliberación, y (3) 
toma de decisión en el cáncer ovárico.
Métodos: Se completó una búsqueda bi-
bliográfi ca que incluía investigación original 
acerca de la toma de decisión del tratamiento 
médico sobre el proceso de enfermedad del 
cáncer de ovario. 
Resultados: el intercambio de informa-
ción mostró que los pacientes y los médicos 
sienten que la expectativa de vida es el tema 
más importante. Los médicos informan que 
no discuten esto en el diagnóstico inicial. Las 
ayudas a la decisión pueden emplearse como 
una herramienta para asegurar la informa-
ción. El nivel de deliberación es el menos 
investigado. No hay información sobre el rol 
que los pacientes y médicos toman. Con la 
excepción de una herramienta basada en In-
ternet, no hay investigación sobre como eli-
citar las preferencias del paciente. Durante la 
toma de decisión del tratamiento, las mujeres 
no perciben que ellas tengan opciones de tra-
tamiento aunque sienten que están tomando 
una decisión. El “no tratamiento” no se con-
sidera una opción. 
Conclusiones: la toma de decisión sobre los 
tratamientos en cáncer de ovario esta progresi-
vamente siendo valorada. El nivel de intercam-
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Abstract
Objectives: To describe what is known 
about the three stages of treatment decision 
making (TDM) in the medical encounter: (1) 
information exchange, (2) deliberation, and 
(3) making the treatment decision for ovarian 
cancer (OC). 
Methods: A literature search was comple-
ted including original research on TDM as it 
pertained to the disease continuum of OC. 
Results: Information exchange shows that 
patients and physicians feel that life expectan-
cy is the most important issue. Physicians re-
port that they do not discuss this at initial diag-
nosis. Decision aids could be used as a tool to 
ensure that information. The deliberation stage 
is the least researched. There is no information 
on the role that patients and physicians take. 
With the exception of one internet based tool, 
there is no research on how to elicit patient 
preferences. During making the treatment de-
cision, women do not perceive that they have 
treatment options yet they feel they are making 
the decision. “No treatment” is not considered 
to be an option. 
Conclusions: TDM in OC is increasingly be-
ing evaluated. The stage of information exchan-
ge has been assessed in greater depth compa-
red to that of the other stages.
Key words: Ovarian Cancer, Decision Ma-
king.
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Introduction
Globally, ovarian cancer accounts for 
3% of all cancers in women. Worldwide it 
has an age standardized incidence rate of 
6.3 per 100,000 and a mortality rate of 3.8 
per 100,000 women. Ovarian cancer has 
the highest mortality rate of all cancers of 
the female reproductive system(1). Of those 
women who are diagnosed with ovarian 
cancer, 70% will die of their disease. If 
the cancer is limited to the ovary, then on 
average a woman’s 5 year survival is 80%; 
however, only 23% of women present 
with localized disease. Most women who 
have ovarian cancer are diagnosed when 
the disease is widespread/advanced; their 
average survival rate at 5 years is less than 
20%.
Usually when a woman seeks medical 
attention, she has symptoms of abdominal 
bloating, pelvic discomfort or abnormal 
vaginal bleeding. This woman already has 
advanced disease. Once the diagnosis of 
possible ovarian cancer is made, there are a 
series of treatment decisions to be made. If 
the woman presents with an isolated mass, 
one treatment decision is whether to have 
her surgery by laparotomy (large incision) 
or laparoscopy (using 4 or more very small 
incisions and a camera). The goal of surgery 
is to make a histologic diagnosis, identify 
the extent of disease spread and to remove 
as much tumour as possible. There are pros 
and cons with either route of accessing the 
abdominal cavity.
Once ovarian cancer is histologically 
confi rmed, the goals of care become 
control of symptoms and prolongation 
of life. Thus the decision at this point in 
the journey involves whether or not the 
woman agrees to using chemotherapy, 
which agents and whether this will be by 
an intravenous or intraperitoneal route. A 
variety of drugs are available and these 
can be used alone or in a number of 
combinations with varying effectiveness. 
Both the access route for administering 
the drug and the drug chosen have unique 
potential side effect and potential benefi t 
profi les. 
Ovarian cancer has a variable course 
characterized by initial response to 
chemotherapy often followed by relapse 
and progression of disease. When the 
disease recurs, the woman will always 
live with disease. From time to time she 
is likely to have complications related to 
the disease or the treatment. Eventually 
she will die of her disease. At the time of 
disease recurrence, the woman needs to 
decide if she wishes active management 
of the tumour with further chemotherapy 
or clinical trials (assessing novel agents), 
or focus on symptom management alone. 
In summary, management of ovarian 
cancer throughout the cancer journey from 
diagnosis to death can impact quality of 
life(2,3), symptoms and psychological well-
being(4). 
Stages in Decision Making
A recurring theme in the ovarian 
cancer journey is the necessity of making 
a treatment decision at different points in 
the disease continuum. For the sake of this 
manuscript, treatment may refer to surgery, 
chemotherapy or symptom management 
only. After a review of the patient’s story, 
physical exam and tests results, the patient 
and physician meet together to determine 
bio de información ha sido evaluado en mayor 
profundidad comparado con otros niveles.
Palabras clave: Cáncer de ovario, toma de 
decisión. 
What we know about treatment decision making in ovarian cancer  271
the most appropriate treatment. This 
process typically involves three stages: 
1. Information exchange about disease 
management, 2. Deliberation or eliciting 
patient (and in some cases, physician) 
values and preferences about the treatment 
options and, 3. Making a decision about 
the treatment to implement(5) (Table 1). 
Information exchange is the relay of 
information usually from the physician to 
the patient but it can be from the patient 
to the physician. The content and extent 
of the information exchange may vary 
depending on the type of encounter but 
for the purposes of this discussion, the 
information exchange should provide 
at minimum the disease and treatment 
related information for making a treatment 
decision. Deliberation is the process of 
identifying values (i.e., what is important for 
that individual – patient and/or physician) 
and expressing and discussing treatment 
preferences. Making the treatment decision 
can be something the physician or patient 
does alone or can involve both parties. 
Making a decision implies that there are 
treatment options. 
In this paper we will discuss what is 
known about the three stages of treatment 
decision making (ie., information exchange, 
deliberation including the process of 
eliciting patient preferences and making 
the treatment decision) in the context of 
ovarian cancer. Each stage will be discussed 
along the continuum of the ovarian cancer 
journey from onset of symptoms, through 
diagnosis, initial treatment, recurrence and 
palliation. 
 
METHODS
A literature review was conducted 
using Medline and Google. The key words 
included: treatment decision making, 
information exchange, communication, 
preferences, and ovarian cancer. We 
retrieved 260 abstracts in the English 
language. Manuscripts were retrieved if the 
abstract indicated that the article described 
original research on the treatment decision 
making process in women with ovarian 
cancer. Manuscripts were excluded if they 
1) were written in a language other than 
English, or 2) were comprised of non-original 
research. Each manuscript was read and 
the contents summarized. This included: 
study population, study objectives, study 
type, results, and information about any of 
the 3 stages of decision making. The results 
were grouped according to the information 
they provided about one of the 3 stages 
of decision making. The information on 
each stage was summarized and then 
on several occasions discussed with the 
chapter authors. 
Findings
Specifi c research themes addressed in 
the literature on information exchange 
include: 1) reason for information seeking, 
2) the kinds of information that patients 
and their physicians think are important 
for patients to receive in the medical 
encounter, 3) satisfaction with the 
information exchanged, 4) the kinds of 
information that ovarian cancer specialists 
communicate to patients in the medical 
encounter, 5) the information women 
hear during the encounter, 6) physician 
communication styles, and 7) physician’s 
use of decision aids to communicate 
information on treatment risks and benefi ts 
to patients. Research themes related to the 
process of deliberation about treatment 
options in the medical encounter include: 
1) the role patients want in TDM, 2) the 
values of women with ovarian cancer, 3) 
their treatment preferences, 4) Physician’s 
treatment recommendation, and 5) factors 
that aid in the deliberation. Research 
themes pertaining to making the treatment 
decision include: 1) the range of options 
discussed, 2) women’s perceptions about 
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no treatment as an option, 3) how the 
treatment decision is made, and 4) factors 
that appear to infl uence the treatment 
decision. 
1. Information Exchange
We usually expect that the direction 
of information exchange in the medical 
encounter is predominantly from the 
physician to the patient. However, especially 
in this era of access to the internet, second 
and third medical opinions, this process 
could also involve the patient bringing 
information either about her disease or other 
management strategies to the physician. 
Thus information exchange encompasses 
not only the fl ow of information but the 
direction, the type of information and the 
amount of information.
1.1. Reason for information seeking
Research suggests that women with 
ovarian cancer want information about 
their disease and its treatment for several 
reasons; it will help them cope better with 
treatment side effects(6), or to enhance their 
psychological autonomy(7). Some authors 
point out that women want information 
regardless of their desire to be responsible 
for making a treatment decision(7,8). For the 
purpose of this paper, we will try to focus 
on the kind of information a patient requires 
in order to make a treatment decision. 
1.2. Kind of information 
The “kind” of information involves not 
only the type of information but also whose 
perspective is important in identifying 
what information should be exchanged. 
The ovarian cancer literature provides 
some insight into these questions from 
the perspectives of the patient, society 
and physician. In a study of the medical 
encounter in the context of ovarian cancer 
conducted by Feldman Stewart in Canada 
in 1996(9), eighty three women with 
ovarian cancer, twenty volunteers who did 
not have cancer, and one hundred and 
sixteen physicians were asked to rate the 
importance of 57 questions in terms of 
whether they should be discussed during 
the medical encounter. Importance was 
indicated on a 100 mm visual analogue 
scale anchored by “not important” on 
the left to “very important” on the right. 
The patients and volunteers felt that 
information related to life expectancy was 
most important (median 92.1 and 96.2 
respectively). The patients and volunteers 
felt that issues of cost of treatment were 
least important (median (rank) 47.0 (57) 
and 50.0 (55) respectively). In part this 
may refl ect the fact that in Canada, cancer 
treatment is publicly funded. The patients 
and volunteers were congruent in ranking 
what were high and low priority topics of 
information exchange. 
In this study, the Canadian physicians 
who actively manage women with 
ovarian cancer in major cancer centres 
completed the same questionnaire. The 
physicians also felt that information 
related to life expectancy was most 
important (median 88.4 physicians) 
and they concurred that issues of cost 
of treatment were least important 
(median (rank): 16.5 (57) physicians). 
The physicians felt that information on 
diet was not important in contrast to 
patients; patients felt that information on 
sexual attractiveness was not important 
in contrast to physicians. On the most 
important and least important issues to 
be discussed in the medical encounter, 
all three groups agreed. On other issues, 
the patient and volunteer groups were 
more similar in their views than were 
either to the physician group. 
Elit (1996)(10) conducted a study of 
six physicians after observing a medical 
encounter at the point on making a treatment 
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decision for fi rst line chemotherapy. All 
physicians indicated that the encounter 
should include information concerning 
the patients’ disease status, available 
management options, chemotherapy, 
treatment process, and potential side 
effects. Physicians indicated that they 
would not give patients survival information 
at this point in the cancer journey unless 
the patient specifi cally asked. Those same 
physicians said that if they were the patient, 
they would want survival information. 
When asking 48 women whether survival 
information should be discussed, both 
women without cancer and women who had 
already received fi rst line chemotherapy for 
ovarian cancer advised that the physician 
should ask the patient whether or not she 
wanted to hear the survival information(10). 
Some women indicated that prefer not to 
hear this information.
Stewart 2000(11) surveyed 139 Canadian 
women at any point in the ovarian cancer 
journey. Six different questionnaires were 
used to obtain demographic information, 
psychological functioning, preferences, 
and specifi c information needs. These 
women wanted information on the status 
of their cancer (is there cancer in their 
body, how will they know if it has come 
back), treatment concerns (what are the 
various treatments recommended for this 
cancer and how successful are they), and 
self care and empowerment (what they 
could do to improve their recovery). These 
information preferences were stable across 
the illness trajectory.
Factors that infl uenced the kind of 
information patients wanted have been 
described by several authors. In this 
same study(11), she identifi ed that higher 
education levels were positively related to 
preferences for more detailed information 
among study participants (p<0.05). Older 
woman (age over 60 years) sought out 
information focused on physical aspects 
of her health (p<0.05). The literature 
suggests that the type of information that 
women with ovarian cancer want may 
be infl uenced not only by the woman’s 
age and level of education, but also prior 
experience with health care issues(10,12), 
personal experience with disease(13), 
anxiety(14) and depression.
1.3. Satisfaction with information 
exchange
To understand whether patients are 
satisfi ed with the information given in the 
medical encounter, Fitch conducted a cross-
sectional survey of 315 Canadian women 
living with ovarian cancer(6,14). Eighty 
percent of women felt adequately informed 
and were satisfi ed with communication 
with their physician (mean 4.1-4.5 out of 5 
point scale). The information they felt was 
most important to have was information 
about their particular situation with cancer, 
treatment, side effects and symptom relief 
(Ranking of 74-87.9 out of 100). Women 
were least satisfi ed with the information 
they received about emotional reactions, 
counseling services, access to other women 
with ovarian cancer, self-help groups and 
complementary and alternative therapies 
(Scores of 27 to 47 out of 100). 
Women perceived that access to 
information changed during the journey 
with ovarian cancer. Howell 2003(15) 
conducted individual interviews with 18 
Canadian women at the time of ovarian 
cancer recurrence. They indicated that 
it was more diffi cult to fi nd information 
on treatment options at recurrence as 
compared to front line disease. These 
women felt they had to push the medical 
team for further information on treatment 
options. Some felt that their treatment 
options were limited because of their 
geographic location or lack of access to 
other subspecialists. 
When women did not obtain the 
information they felt they required, they 
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were resourceful at getting information. 
Finn 2000(8) interviewed 6 women from 
Hamilton, Canada with recurrent ovarian 
cancer. When these women did not get the 
information they wanted, they returned to 
the physician with a list of questions or with 
a family member who could advocate for 
their information needs. Zieband 2006(16) 
conducted individual interviews with 43 
women with ovarian cancer in the United 
Kingdom. These women indicated that they 
used second opinions as an opportunity 
to obtain more information about their 
disease and treatment options.
1.4. What information do physicians 
provide to patients?
To determine what information 
physicians actually provide to patients 
during the medical encounter, our 
group(10) observed a number of physician-
patient interactions where fi rst line 
chemotherapy was discussed for women 
newly diagnosed with ovarian cancer. 
Physicians consistently provided patients 
with information concerning their disease 
status, the available management options 
(surgery followed by chemotherapy, 
chemotherapy alone, and supportive care 
only), chemotherapy and the treatment 
process. Potential side effects were 
described by one-third of physicians. Only 
one out of six physicians discussed the 
goals of treatment as prolonging survival 
time. In a questionnaire completed by 
the physicians after the observed medical 
encounter, physicians overestimated 
the information they said they would 
give a patient when compared with 
the information they actually gave the 
patient in the observed physician-patient 
interaction (kappa=0.52(10).
1.5. To what extent do women hear and/
or understand the information presented 
to them in the medical encounter?
There is no study in the ovarian cancer 
literature that documents the extent to 
which women understand the information 
imparted to them in the medical encounter. 
Such work has been completed in other 
cancer disease sites. Whelan showed 
that patients with breast cancer do not 
always ‘hear’ or remember the information 
presented in the patient physician 
encounter(17) This is an important fi nding 
because if the physician believes they 
explained the outcomes information but 
the patient does not understand the terms 
or the implications of this information, the 
patient may walk away from the encounter 
feeling dissatisfi ed or uninformed following 
the medical encounter and may act on 
misperceptions of the meaning of the 
information. 
Using a qualitative study design with 
one on one interviews, Fitch in 2002(14) 
interacted with 18 women at the time 
of their diagnosis of ovarian cancer. She 
found that these women felt that they were 
given little information or had little access 
to information at the time of diagnosis. 
She identifi ed that this particular medical 
encounter occurred at a time when women 
were experiencing marked anxiety and 
depression, impaired social functioning, 
fatigue, pain, compromised sexuality 
and psychological distress. The women’s 
physical and/or emotional distress may 
have impeded their ability to receive or 
process the information imparted by the 
physician. 
Our group(18) interviewed 21 Canadian 
women at the point of making a treatment 
decision for fi rst line chemotherapy. We 
identifi ed that women understood that the 
treatment had both potential survival and 
quality of life benefi ts. They could clearly 
articulate the potential risks. However, the 
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women spoke about being overwhelmed 
by the severity of their illness and grief 
over the cancer diagnosis. Jolicouer(12) 
conducted 21 individual interviews with 
women with recurrent ovarian cancer 
from Ottawa, Canada. All of the women 
understood that their disease was not 
curable. However, her research group 
indentifi ed that the longer the time from 
the decision making encounter to the 
interview, the greater the loss of detailed 
information retention among study 
participants. Howell 2003(15) conducted 18 
Canadian women with recurrent ovarian 
cancer. They found that the label of cancer 
was emotionally charged and the degree 
of unwellness may have prevented some 
women from taking in the details of the 
information presented. Thus, many factors 
related to the patient may infl uence her 
ability to receive and understand the 
information delivered during the medical 
encounter.
1.6. Physician Communication Style
Elit(13) noticed in a series of interviews 
with 26 Canadian women with ovarian 
cancer at the time of fi rst recurrence, that 
there were perceived differences among 
women about their physicians’ style of 
information giving. The physician’s styles 
varied on 5 dimensions: 1) physician’s 
demeanor (quiet and business like, 
friendly, direct approach and admits 
uncertainty); 2) how the treatment options 
were presented to the patients (sequential - 
one option provided for each event verses 
simultaneous - where several options were 
given and the patient chooses one), 3) the 
depth of information provided (patient had 
to ask questions to illicit details versus 
information provided without prompting), 
4) how the information was presented 
(verbal only, verbal with writing or other 
aids) and 5) whether or not a treatment 
recommendation was forthcoming. 
An examination of the literature on 
the infl uence of physicians in the TDM 
process in other cancers shows that poor 
communication of disease status and 
treatment benefi ts and risks and options 
lead to poor outcomes such as patient 
dissatisfaction, lack of patient adherence 
to a treatment plan, poorer self reported 
health, poorer physician satisfaction and 
higher malpractice claims(19). However, 
randomized trials of strategies to improve 
physician communication have not 
shown that the strategies tested improved 
communication scores(19), lower patient 
distress(20), or lower patient or family 
anxiety(21). There is no literature on the 
impact of physician style on information 
giving, deliberation or making the treatment 
decision in ovarian cancer. We are currently 
undertaking research on this topic.
1.7. Decision Aids
To enhance the information exchange 
in the medical encounter, there has 
been research assessing the usefulness of 
decision aids (DA). DAs are tools intended 
to help patient with decisions about their 
health care. They provide information on 
the disease, goals of treatment, treatment 
options, side effects and outcomes in a 
standardized way. DAs have been shown 
to improve knowledge without increasing 
anxiety(22). DAs can involve high technology 
interactive videos or be low tech, using 
fl ip charts with an audio aid. The Decision 
Board (DB) is one example of a DA. It is 
an enabling tool for information transfer 
from the physician to the patient; it is a 
supplement to the physician consultation 
but does not replace it. DBs were originally 
modeled on standard clinical practice with 
two-way interaction and so meet the ethical 
and legal principles of information consent 
and information transfer. These aids can 
be easily and cheaply modifi ed as new 
relevant data are reported. They are used 
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to present information on potential risks 
and benefi ts in an unbiased fashion. DBs 
have been used in the context of ovarian 
cancer to elicit treatment preferences for 
fi rst line chemotherapy (10) and at the time 
of recurrent disease(23). The DB can provide 
an unbiased way of providing information 
(i.e., blinding the patient to the names 
of the drugs). They can also be used to 
objectively present survival information. 
The manner in which this information 
(ie., percent survival at a point in time 
versus median survival) is presented can 
infl uence choice(10). With some DBs, the 
patient can leave the patient-physician 
interaction with an 8”x11” printed version 
of the DB. The hand-out-version allows 
patients to reconstruct what the heard 
the doctor says in the patient-physician 
interaction. The DB has been shown to 
improve the retention of disease, treatment 
and outcome information.
To date the ovarian cancer literature 
explores the decision board uses in 
research settings for research purposes and 
not in regular clinical practice settings. 
Given the concerns voiced by patients 
that they want more information and 
given the research that shows physicians 
often do not provide the information they 
feel should be provided in the patient-
physician interaction, the DB may be one 
adjunct to improve the information transfer 
component of TDM. 
2. Deliberation
The deliberation stage of decision-
making refers to the process of identifying 
values, expressing and discussing treatment 
preferences. How deliberation proceeds 
in part depends on the role patients and 
physicians assume in the information 
exchange stage. Both the patient’s role and 
the physician’s role is dynamic and may 
stay the same or change between as well 
as during each of the 3 stages. 
2.1. What role do ovarian cancer patients 
want in deliberation?
Patient preference for participation in 
decision making can change depending 
on where the patient is in her journey 
with the disease. There is no literature that 
specifi cally addresses patients’ preferred 
role in deliberation. There is literature about 
women’s preferred role in the treatment 
decision making process in ovarian cancer 
which may provide insight into the role 
they may want in deliberation. Stewart’s 
work(11) using questionnaires showed 
minimal fl uctuation in preferences about 
who should make the treatment decision 
when women were fi rst diagnosed, at the 
time of treatment and after treatment. In 
contrast, during individual interviews with 
women at fi rst recurrence, both Howell(14) 
and Elit(13) identifi ed that women felt their 
participation in decision making was more 
active. The authors did not elaborate on 
what “more active” means. In Howell’s 
work, women felt they were more involved 
in decision making because of their 
experience with fi rst line treatment and 
because they now had more knowledge 
about the disease. In Elit’s work, patients 
with recurrent ovarian cancer sensed 
that the process of decision making was 
more straightforward. It is not clear if this 
means that at this point in time, they are 
more comfortable communicating within 
the cancer system or in articulating their 
preferences.
Deliberation can occur between the 
patient and physician alone or in the 
presence of family members or friends. 
Again there is no focused research on 
this issue and in particular as it pertains 
to deliberation. However, in some of the 
studies, both physicians and patients have 
indicated the desire to have a patient 
advocate in the room during the TDM 
process(8,12,13).
What we know about treatment decision making in ovarian cancer  279
Deliberation can take place directly 
with the physician or health care team 
or deliberation can occur outside the 
medical encounter. For example, the 
patient can work with an internet tool that 
is usually algorithm based. There are a 
few internet programs that allow women 
with ovarian cancer to work through a 
treatment decision in the comfort of the 
home on the computer. These tools are 
different than providing information. They 
ask patients specifi c questions about their 
disease (ie., stage, grade, histology). They 
provide treatment information and options. 
They help patients clarify their values and 
rate some treatment options as higher and 
lower in preference. The American Cancer 
Society website hosts a treatment decision 
tool from NexProfi ler called the “treatment 
option tool”. It asks specifi c demographic 
questions to provide detailed information 
for treatment options for patients with 
several types of cancer including ovarian 
cancer. The tool focuses on providing 
information and aiding the deliberation 
process by having the patient list all the 
positive things a women and her doctor 
think concerning a treatment choice in 
one column and all the risks in a second 
column(24). 
2.2. What values are important to women 
with ovarian cancer?
The concept of values is elusive. 
Some of the literature equates or freely 
interchanges “values” with “preferences”. 
For the purpose of this chapter we defi ne 
“values” as those things that are held in 
highest regard or most important for that 
individual. Values shape the decisions 
a person makes. They are the drivers or 
motivators or things for which we will 
sacrifi ce other things. Values answer the 
question “Why do I do what I do?” Values 
are acquired and so they can change. 
As it pertains to decision making in 
women with ovarian cancer, values may 
infl uence the role the woman wants in the 
decision making process (ie., autonomy), 
and the treatment outcome that is most 
important to her (ie., living as long as 
possible, quality of life, time with family). 
There is no literature in ovarian cancer 
that identify which are the important 
values, how these values infl uence role 
or the treatment decision, or how values 
may change during the journey with the 
disease.
2.3. What are the treatment preferences 
in women with ovarian cancer?
We will use the phrase “patient 
preferences” to mean that the patient has 
explicitly identifi ed a management strategy 
that refl ects her values, beliefs and life 
goals, her understanding of her illness and 
her understanding of the potential risks 
and benefi ts associated with treatment. At 
the point of making a decision concerning 
fi rst line chemotherapy for ovarian 
cancer, our group(10) used a decision 
board to determine patient preference 
for treatment. We reviewed the DB with 
37 women volunteers without cancer, 
11 women with ovarian cancer who had 
completed chemotherapy and 12 women 
at the point of making the treatment 
decision for fi rst line chemotherapy. 
The DB provided information about the 
disease, two chemotherapy treatment 
options, how they are administered and 
the frequency of expected side effects 
and survival information for each option. 
The names of the drugs were not used 
and side effects were presented by bar 
graphs. Women who had just completed 
surgery for advanced ovarian cancer who 
were at the point of TDM were given 
a copy of the board and had 24 hours 
to ponder the information. One-third 
of the women chose an older treatment 
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regimen with platinum cyclophosphamide 
and two-thirds chose platinum-taxol (the 
then novel treatment). No factors that we 
studied (ie, demographic characteristic, 
depression scores, quality of life score) 
predicted treatment choice. At this point in 
the disease journey, more patients valued 
survival more strongly than quality of life. 
The limitations of our study were that the 
treatment choice using the decision board 
may or may not have been the treatment 
ultimately delivered. How other factors in 
the patient-physician interaction affect the 
fi nal choice of treatment actually taken still 
need to be determined.
Donovan 2002(23) probed the preference 
for management when a woman 
developed her fi rst recurrence from 
ovarian cancer. One management option 
involved further chemotherapy with a less 
than 20% chance of response. Another 
option involved no active management of 
cancer but symptom management for the 
consequences of the cancer; for example, 
using antinausea medication for nausea 
and vomiting or removing fl uid from the 
abdomen periodically for ascites. Donovan 
interviewed two groups of women. One 
group (n=81) included women who were 
currently receiving fi rst line treatment for 
ovarian cancer. The second group (n=75) 
were women without a personal history 
of cancer. Women with ovarian cancer 
were fi ve times more likely to choose 
salvage chemotherapy compared to non-
cancer patients. They were more willing 
to tolerate the toxicity of chemotherapy 
even though they had non-curable disease. 
The one discriminating factor was that 
women who had a diffi cult time with fi rst 
line chemotherapy (this involved 12.5% 
of the sample) were less likely to choose 
chemotherapy when the disease recurred. 
Most women switched to a decision for 
palliative care when they were told they 
had a survival of 3 months or less. 
Twenty-fi ve percent of ovarian cancer 
patients said they would never switch to 
palliative care even if survival was less 
than 1 week. Palliative care means no 
hope for survival; however, hope seemed 
to be derived from the fact that treatment 
was offered even if the treatment is futile. It 
appears that even in the context of decision 
aids where there is clear information on 
treatment options; patients may not use 
research evidence to make what most of 
us would term a “rationale” decision. This 
may mean that the patient does not believe 
the opinion of the health care team that 
they are dying or the estimate of time prior 
to their demise. It may mean that patients 
do not wish to think or acknowledge their 
demise (ie., give up hope). It may mean 
that patients do not want to use medical 
evidence to make their management 
decision. What this shows is the importance 
of patient preference. Decision making is 
not just about information exchange; but 
rather, it is about how this information 
takes on meaning for the patient.
2.4. Treatment recommendations: what 
role do they play in deliberation?
There are some physicians that provide 
patients with the information about 
treatment options and potential side effects 
and benefi ts but then stop and allow the 
patient to articulate their treatment choice. 
Zieband 2006(16) conducted individual 
interviews with 43 women with ovarian 
cancer in the United Kingdom. These 
women found that being offered a treatment 
choice was not welcomed. When the 
reason for the choice was not provided 
(ie., not enough information to understand 
why a choice was even being discussed) or 
understood, the fact that they were given a 
treatment choice made them feel panicky 
and they tried to second guess what they 
thought the doctor really wanted them to 
do. Zieband found that if the woman felt 
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the doctor was unwilling to express his or 
her own preferences this led to confusion 
and concern about the right management. 
The general population is not used to being 
asked about their preferences and such a 
question can surprise or shock people. 
Zieband suggested that clinicians need to 
explain about clinical uncertainty and how 
individual values and preferences may relate 
to treatment decisions. David Mechanic(25) 
a well known medical sociologist, has 
observed that people want to feel part of 
their health care, but they don’t want to 
be abandoned to making decisions all on 
their own. When a doctor says, “Here are 
your options” without offering expert help 
and judgement, this is often seen as a form 
of abandonment. Schwartz(26) is concerned 
that patients are overwhelmed when the 
opportunities are so numerous. Instead of 
being in control, patients loose the ability 
to cope. Being forced to choose in a life 
and death situation can becomes a grave 
burden to patients and if the choice turns 
out to be wrong it can lead to intense 
regret. 
There are some physicians that 
provide women with only one treatment 
option or if other options are provide, 
the physician gives a strong treatment 
recommendation. When the physician 
provides a treatment recommendation, this 
refl ects the physician’s understanding of the 
information, his values and preferences. 
There is some ovarian cancer literature 
on the impact of providing treatment 
recommendations. In Jolicoeur’s work(12) 
with 21 women with recurrent ovarian 
cancer, during the individual interviews, 
half of the women sensed that the doctor 
knew how they would respond to treatment. 
The physician’s treatment recommendation 
became the treatment they felt comfortable 
pursuing. In our work with women at 
the same point in the journey(13), the 26 
women who underwent a semi-structured 
interview indicated that they felt that 
they made the treatment decision and /or 
infl uenced the timing of the chemotherapy. 
The women appeared to describe a process 
of coming to terms with living with cancer 
and accepting the treatment that their 
physician recommended. It appears that 
when there is a treatment recommendation 
made either spontaneously or upon the 
request of the patient or her advocate, 
this strongly infl uences the patient’s future 
management.
2.5. What other factors aid in the 
deliberation phase?
In our study of women making a 
decision for fi rst line chemotherapy for 
ovarian cancer(18), 21 women felt that 
they gleaned support for their treatment 
decision by individual’s who advocated 
for them (ie., spouse, family, friends), their 
faith and past experiences in the cancer 
system (ie., personal previous malignancy 
or journeying with a spouse or parent 
who had cancer). Hindrances to making 
a decision included people who were 
negative, the label of cancer and their 
employers. Our work suggests that both 
the treatment and time of treatments vary 
and are infl uenced by factors external to 
the clinical context such as social networks 
and life events. Hence it is important for 
oncologists to promote an environment 
where other factors have time to interact 
with the information exchanged.
The current literature is lacking on how 
the deliberation phase affects patients (ie., 
anxiety, depression, satisfaction with the 
decision), how long this process should 
last, and to what extent and how other 
factors (time alone, time talking with friends 
and family, discussions with other health 
care providers) infl uence the deliberation 
process. There are unanswered questions 
concerning strategies that can help patients 
make their implicit values explicit and how 
this may or may not impact on treatment 
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preferences, how physician’s values and 
preferences can infl uence this deliberation 
process and patient satisfaction with the 
decision or compliance with treatment. 
3. Making the Treatment Decision 
The culmination of the process of 
information exchange and deliberation 
is making the decision. It is the actual 
verbalizing of a treatment choice and 
moving forward with a treatment plan. In 
this section we are going to reviews 1) What 
do treatment options/choices mean to the 
patient? 2) Is no treatment, an option? 3) 
What role patients want, 4) Making the 
treatment decision, and 5) Factors involved 
in abdicating the treatment decision to the 
medical team.
3.1, The range of options discussed
One would think that making a 
treatment decision implies that the patient 
has management options. In our work using 
individual interviews with 21 women at the 
time of fi rst line chemotherapy for ovarian 
cancer(18), we noted that most women did 
not perceive that they had a treatment 
choice yet they felt that they made the 
decision. Few women perceived that they 
were given a choice between 1 versus 2 
drugs which suggests that physicians may 
have only offered one option as endorsed 
by the practice guidelines (i.e., a 2 drug 
regimen). As well, patients may not have 
recognized “no treatment” as an option. 
In other words, the patients’ decision style 
was a process of coming to terms with the 
disease and the recommended treatment. 
Interestingly, both our respondents and 
those of Jolicoeur(12) felt the physician knew 
which treatment was “right” for them and 
were confi dent in their cancer physician. 
In Jolicoeurs individual interviews with 21 
women with recurrent ovarian cancer, 13 
perceived there was a decision to make 
and 5 felt they had received treatment 
options. It is not clear if the other 8 women 
perceived that the treatment decision was 
agreeing or disagreeing with the treatment 
recommendation. It appears that making a 
treatment choice for patients is not about 
recognizing options or choosing between 
options, rather it means coming to terms 
with a treatment recommendation.
3.2. Women’s perceptions about no 
treatment as an option
During the journey with ovarian 
cancer, one of the options is always – 
not to intervene, or as some phrase it, 
symptom management (alias palliative 
care). For example, the symptom of pain 
is managed with analgesics, shortness of 
breath is management by taking fl uid off 
the lung but this is done within the context 
of no cancer fi ghting treatment (like 
chemotherapy). As described above, in our 
study with 26 women at the point of fi rst 
line chemotherapy for ovarian cancer, “no 
treatment’ did not appear to be recognized 
as an option. At the point of disease 
recurrence, when there is only a 20% or 
1 in 5 chance that any chemotherapy will 
cause the cancer to shrink, the concept of 
“do nothing is not an option” is a theme 
that surfaces again. In Jolicoeur’s study(12) 
of 21 women with recurrent ovarian 
cancer, a third of those interviewed felt 
they received treatment options - with 
no treatment as one of the options. These 
women felt that to do nothing was not 
a viable option. In Zieban’s individual 
interviews with 46 women with recurrent 
disease in the United Kingdom(16), “no 
treatment” was not seen as an option if 
you wanted to survive. It appears from 
Donovan’s work in women with fi rst line 
chemotherapy that the closer the certainty 
of death(23), the more likely women will 
shift to a symptom management decision; 
however, 25% of women with ovarian 
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cancer say they will never shift. Whether 
this choice is stable outside of the research 
hypothetical setting compared to reality, 
has yet to be determined.
3.3. How the treatment decision is made
The role the patients plays in the 
decision making process is dynamic; it 
may change between the 3 stages of DM 
or even during one of the stage. Not all 
women with ovarian cancer want the same 
role in decision making. Stewart(11) asked 
105 women from Toronto Canada, at any 
point in the journey with ovarian cancer: 
Who should make the treatment decision? 
Approximately 20% wanted the doctor to 
make the decision, 15% wanted to make 
the decision themselves and 60% wanted 
to share the decision with the doctor. 
Jolicoeur(12) in individual interviews with 21 
women with recurrent disease found that 
they felt they played the decision making 
role they preferred. Elit(13) showed in 21 
women at the point of making a treatment 
decision for fi rst line chemotherapy for 
ovarian cancer, women indicated that they 
wanted to be involved in the TDM process. 
It was not clear whether “involvement” 
meant being informed, assessing their 
values and preferences and/or making the 
decision. Sutherland suggested that some 
women want information but they do 
not want the responsibility for making a 
treatment decision. The literature suggests 
that in patients with other types of cancer, 
they are more likely to want the physician 
to make the treatment decision(27) especially 
if they are older(28-30), married(28), women 
and less educated(29,31).
3.4. Factors that appear to infl uence the 
treatment decision 
A repeated message in all of the 
individual interviews was that making a 
treatment decision was coming to terms 
with the treatment recommended by the 
physician. Fitch(6) conducted individual 
interviews with 18 women. They articulated 
minimal involved in initial treatment 
decision making and the treatment 
decision was made by physician. Patients 
went along with the decision because they 
wanted help for the discomfort they were 
experiencing or because they felt did not 
know enough about ovarian cancer or its 
treatment to make a contribution to the 
decision. As described in section 2.4 a 
few women indicated that they actively 
chose to let the medical team make the 
treatment decision for them, or they do 
not recognize being actively involved in 
the decision and just went along with the 
treatment recommendation proposed by 
the medical team.
3.5. Factors involved in abdicating the 
decision to the medical team.
In part, the woman’s lack of involvement 
in making the treatment decision is 
undergirded by an urgency to make the 
decision. In Fitch’s 2003 work(6), the 18 
Canadian women with ovarian cancer 
who noted that the initial discussion of 
the disease evoked shock and fear, usually 
were quite ill at the time of diagnosis. 
They felt incapable of participating in 
the decision making process because 
of lack of knowledge. They felt rushed 
through the decision making. Our group(18) 
interviewed 21 Canadian women when 
initially diagnosed with ovarian cancer. We 
identifi ed that women felt overwhelmed by 
the severity of their illness and they felt 
they needed to make a treatment decision 
right away in order for the treatment to 
reverse their dire symptoms.
Summary
Ovarian cancer is a journey from 
diagnosis and adjuvant therapy through 
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recurrence and ultimately the time prior 
to death (palliative period). There are 
decisions that need to be made concerning 
management of the disease all along 
this continuum. The decision making 
process includes information exchange, 
deliberation and making the decision. There 
is a breadth of literature available on the 
stage of information exchange; however, 
there has been minimal exploration on the 
stage of deliberation. Most of the research 
comes from qualitative and survey studies. 
Most of the studies have been done in the 
Canadian context, with little work available 
in ovarian cancer from other jurisdictions. 
Thus we do not know if cultural differences 
affect the TDM process in this population. 
Interest in the ovarian cancer patient’s 
decision making appears to come from the 
supportive care discipline; perspectives 
may be varied if physicians (who are one 
of the players in TDM) were more actively 
involved in this research. The research that 
is available appears to answer specifi c 
questions without any origin or connect to 
a model of decision making. In contrast, 
the current research has not yet matured 
into a model of decision making. The 
current research does not appear to look 
at decision making over the ovarian cancer 
journey. Thus how preferences change 
over time, how the patient or physician 
desired role in each stage of the three 
stages stays the same or changes has not 
been explored.  
Conclusion
Making a decision concerning treatment 
of ovarian cancer across the woman’s 
journey with the disease is important. 
There is a growing literature focused on 
information exchange, one of the three 
stages of decision making. There is minimal 
research on the stage of deliberation. 
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